Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials
Francisca dos Santos Coelho, Marta Borges‐Canha, Madalena von Hafe, et al.
Diabetes/Metabolism Research and Reviews (2020) Vol. 37, Iss. 6
Closed Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1145
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 670
Treatments for NAFLD: State of Art
Alessandro Mantovani, Andrea Dalbeni
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2350-2350
Open Access | Times Cited: 161
Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15473-15473
Open Access | Times Cited: 47
Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis
A. Lopez, Janine Audrei T. Pajimna
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 19
Effects of empagliflozin on liver fat in patients with metabolic dysfunction–associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial
Ka Shing Cheung, Ho Yu Ng, Rex Wan Hin Hui, et al.
Hepatology (2024) Vol. 80, Iss. 4, pp. 916-927
Closed Access | Times Cited: 17
Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations
Stergios A. Pοlyzos, Stergios Kechagias, Emmanuel Tsochatzis
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 8, pp. 1013-1025
Open Access | Times Cited: 78
Steatotic liver disease, MASLD and risk of chronic kidney disease
Josh Bilson, Alessandro Mantovani, Christopher D. Byrne, et al.
Diabetes & Metabolism (2023) Vol. 50, Iss. 1, pp. 101506-101506
Open Access | Times Cited: 33
Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study
Alfredo Caturano, Raffaele Galiero, Giuseppe Loffredo, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 322-322
Open Access | Times Cited: 25
Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population
Nicholas Chew, Xin Pan, Bryan Chong, et al.
Diabetes Research and Clinical Practice (2024) Vol. 211, pp. 111652-111652
Closed Access | Times Cited: 11
SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD
Moein Ala
Endocrinology (2021) Vol. 162, Iss. 12
Open Access | Times Cited: 46
Diabetes and metabolic dysfunction-associated fatty liver disease
Timothy M. E. Davis
Metabolism (2021) Vol. 123, pp. 154868-154868
Closed Access | Times Cited: 45
Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis
Michael Hendryx, Yi Dong, Jonas M. Ndeke, et al.
PLoS ONE (2022) Vol. 17, Iss. 9, pp. e0274519-e0274519
Open Access | Times Cited: 32
Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease
Stergios A. Pοlyzos, Dimitrios G. Goulis, Όλγα Γιουλεμέ, et al.
Current Obesity Reports (2022) Vol. 11, Iss. 3, pp. 166-179
Closed Access | Times Cited: 29
Bile Acids and Bilirubin Role in Oxidative Stress and Inflammation in Cardiovascular Diseases
Angela Punzo, Alessia Silla, Federica Fogacci, et al.
Diseases (2024) Vol. 12, Iss. 5, pp. 103-103
Open Access | Times Cited: 6
Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Yuyuan Zhang, Xiaobo Liu, Huazhu Zhang, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 24
Unfolded Protein Response Signaling in Liver Disorders: A 2023 Updated Review
Smriti Shreya, Christophe F. Grosset, Buddhi Prakash Jain
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 14066-14066
Open Access | Times Cited: 14
Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso)
Rodrigo O. Moreira, Cynthia Melissa Valério, Cristiane Alves Villela‐Nogueira, et al.
Archives of Endocrinology and Metabolism (2023) Vol. 67, Iss. 6
Open Access | Times Cited: 13
Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review
Lingli Xie, Wenfang Xia
Life Sciences (2022) Vol. 300, pp. 120543-120543
Closed Access | Times Cited: 21
Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease
Kevan Josloff, Jacob Beiriger, Adnan Khan, et al.
Journal of Cardiovascular Development and Disease (2022) Vol. 9, Iss. 12, pp. 419-419
Open Access | Times Cited: 20
Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes
Georgios Tsamos, Dimitra Vasdeki, Theocharis Koufakis, et al.
Metabolites (2023) Vol. 13, Iss. 4, pp. 517-517
Open Access | Times Cited: 12
Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations
Raffaele Galiero, Alfredo Caturano, Erica Vetrano, et al.
Diabetes Metabolic Syndrome and Obesity (2023) Vol. Volume 16, pp. 3669-3689
Open Access | Times Cited: 12
The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus—A Systematic Review
Cristina Bică, Valeria-Anca Pietroșel, Teodor Salmen, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7184-7184
Open Access | Times Cited: 11
SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong
Chi‐Ho Lee, Lung‐Yi Mak, Eric Ho Man Tang, et al.
Hepatology (2023)
Closed Access | Times Cited: 11
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Exploring Systemic Impacts and Innovative Therapies
Parag Jain, Akanksha Jain, Rohitas Deshmukh, et al.
Clinics and Research in Hepatology and Gastroenterology (2025), pp. 102584-102584
Closed Access
Page 1 - Next Page

Scroll to top